Publication Cover
CRANIO®
The Journal of Craniomandibular & Sleep Practice
Volume 33, 2015 - Issue 2
325
Views
12
CrossRef citations to date
0
Altmetric
Sleep

Efficacy of treatment of insomnia in migraineurs with eszopiclone (Lunesta®) and its effect on total sleep time, headache frequency, and daytime functioning: A randomized, double-blind, placebo-controlled, parallel-group, pilot study

, &

References

  • Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain. 1993;53:65–72.
  • Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 2005;45:904–10.
  • Strine TW, Chapman DP, Balluz LS. Population-based U.S. study of severe headaches in psychological distress and comorbidities. Headache. 2006;46:223–32.
  • Sancisi E, Cevoli S, Vignatelli L, Nicodemo M, Pierangeli G, Zanigni S, et al. Increased prevalence of sleep disorders in chronic headache: a case-control study. Headache. 2010;50:1464–72.
  • Tran DP, Spierings ELH. Headache and insomnia: their relation reviewed. J Craniomandib Pract. 2013;31:165–70.
  • Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20:1979–91.
  • Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26:793–9.
  • Krystal AD, McCall WV, Fava M, Joffe H, Soares CN, Huang H, et al. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim Care Companion CNS Disord. 2012;14:PCC.11m01296.
  • Attarian H, Applebee G, Applebee A, Wang BX, Clark M, McCormick B, et al. Effect of eszopiclone on sleep disturbances and daytime fatigue in multiple sclerosis patients. Int J MS Care. 2011;13:84–90.
  • Lettieri CJ, Quast TN, Eliasson AH, Andrada T. Eszopiclone improves overnight polysomnography and continuous positive airway pressure titration: a prospective, randomized, placebo-controlled trial. Sleep. 2008;31:1310–6.
  • Lettieri CJ, Collen JF, Eliasson AH, Quast TM. Sedative use during continuous positive airway pressure titration improves subsequent compliance: a randomized, double-blind, placebo-controlled trial. Chest. 2009;136:1263–8.
  • Lettieri CJ, Shah AA, Holley AB, Kelly WF, Chang AS, Roop SA, et al. Effects of a short course of eszopiclone on continuous positive airway pressure adherence: a randomized trial. Ann Intern Med. 2009;151:696–702.
  • Eckert DJ, Owens RL, Kehlmann GB, Wellman A, Rahangdale S, Yim-Yeh S, et al. Eszopiclone increases the respiratory arousal threshold and lower the apnoea/hypopnea index in obstructive sleep apnoea patients with a low arousal threshold. Clin Sci. (Lond). 2011;120:505–14.
  • Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain (second edition). Cephalalgia. 2004;24(Supplement 1):1–160.
  • American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 1994.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.